AlloMia

The supplied evidence does not describe a commercial entity named AlloMia. The only source provided is a press release about Debiopharm, a privately owned Swiss biopharmaceutical company, and its MultiLINK (MLINK) antibody-drug-conjugate linker technology presented at World ADC San Diego 2026. That document contains no mention of AlloMia, no product, company, ownership, headquarters, or market information tied to the name AlloMia, and no official website or Wikipedia entry for it. Because the identity of the subject cannot be established from the evidence, this entry is intentionally kept short and flagged for review. It should not be assumed that AlloMia is connected to Debiopharm, to antibody-drug conjugates, or to any other business described in the source. If a verifiable official site, trademark record, or encyclopedia entry for AlloMia becomes available, this dossier should be rewritten from that evidence.

1. 1Debiopharm's Pre-Clinical Proof-Of-Concept Research Unveils the Potential of Novel MultiLINK Linker Technology to Overcome Tumor Resistancefinanznachrichten.de
2. 2MEDFAR acquires AlloMia, advancing MYLE as a system of intelligence for clinicsrecorder.ca